Rigel to present R289 data in lower-risk MDS and new fostamatinib results in ITP at ASH 2026 – Rigel
Rigel Pharmaceuticals will present updated Phase 1b data for R289 at the 68th ASH Annual Meeting, in an oral session on 12 December 2026. R289 is the company’s… read more.




